Summary of the 9th meeting of the European Forum on Antiphospholipid Antibodies

Lupus

Volumn 23, Issue 4, 2014, Pages 395-399

  Swadzba, J ^a   Sydor, W J ^a   Kolodziejczyk J ^b   Musial J ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b Fideltronik Sp z oo   (Poland)

Author keywords

antiphospholipid antibodies; Antiphospholipid syndrome

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; COMPLEMENT; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LIPOCORTIN 5; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; RIVAROXABAN; THROMBIN; VITAMIN D;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ARGENTINA; ARTERY THROMBOSIS; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOIMMUNITY; BIRTH WEIGHT; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT BLOOD LEVEL; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; HEART MUSCLE PERFUSION; HUMAN; HYPOCOMPLEMENTEMIA; ISRAEL; KIDNEY DISEASE; LIVEDO RETICULARIS; MEDICAL RESEARCH; META ANALYSIS (TOPIC); PATHOGENICITY; PHYSICIAN; PREECLAMPSIA; PREGNANCY OUTCOME; PREMATURITY; PRIORITY JOURNAL; PROPHYLAXIS; RAYNAUD PHENOMENON; RISK REDUCTION; SCIENTIST; SOLUTIO PLACENTAE; SPONTANEOUS ABORTION; STANDARDIZATION; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; THROMBOSIS; UNITED STATES; VENOUS THROMBOEMBOLISM; VITAMIN SUPPLEMENTATION; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BIOMEDICAL RESEARCH; HUMANS;

EID: 84896121770     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314520841     Document Type: Conference Paper

References (42)

1. Jamrozik J, Jankowski M, Partyka L, Skowiniak A, Swadzba J. Lupus anticoagulant - tajemniczy prokoagulant. Pol Arch Med Wewn. 1993 ; 90: 348-355
2. Musiał J, Swadzba J, Jankowski M, Grzywacz M, Bazan-Socha S, Szczeklik A. Thrombin generation measured ex vivo following microvascular injury is increased in SLE patients with antiphospholipid-protein antibodies. Thromb Haemost. 1997 ; 78: 1173-1177
3. Swadzba J, De Clerck LS, Stevens WJ, et al. Anticardiolipin, anti-β2 glycoprotein-1, anti-prothrombin antibodies and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol. 1997 ; 24: 1710-1715
4. Swadzba J, Iwaniec T, Musial J. Increased level of tumour necrosis factor-α in patients with antiphospholipid syndrome - marker not only of inflammation but also of the prothrombotic state. Rheumatol Int. 2011 ; 31: 307-313
5. Cervera R, Boffa MC, Khamashta MA, Hughes GRV. The Euro-Phospholipid project: Epidemiology of the antiphospholipid syndrome in Europe. Lupus. 2009 ; 18: 889-893
6. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009 ; 68: 1428-1432
7. De Laat B, Van Berkel M, Urbanus RT, et al. Immune responses against domain I of β2-glycoprotein I are driven by conformational changes: Domain I of β(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum. 2011 ; 63: 3960-3968
8. Erkan D, Lockshinet MD. APS ACTION - AntiPhospholipid Syndrome Alliance For Clinical Trials and International Networking. Lupus. 2012 ; 21: 695-698
9. Pierangeli SS, Favaloro EJ, Lakos G, et al. Standards and reference materials for the anticardiolipin and anti-β2glycoprotein I assays: A report of recommendations from the APL Task Force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta. 2012 ; 413: 358-360
10. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost. 2009 ; 7: 1737-1740
11. Devreese KM. Standardization of antiphospholipid antibody assays.. Where do we stand?. Lupus. 2012 ; 21: 718-721
12. De Laat HB, Derksen RHWM, Urbanus RT, Roest M, De Groot PG. 2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood. 2004 ; 104: 3598-3602
13. De Laat B, Derksen RHWM, Reber G, et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of anti-β2-glycoprotein autoantibodies. J Thromb Haemost. 2011 ; 9: 149-153
14. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classiïcation criteria for deïnite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4: 295-306
15. Pengo V, Ruffatti A, Legnani C, et al. Incidence of a first thromboembolic event in asymptomatic carriers of high risk antiphospholipid antibody profile: A multicenter prospective study. Blood. 2011 ; 118: 4714-4718
16. Alarcón-Segovia D, Pérez-Vázquez ME, Villa AR, Drenkard C, Cabiedes J. Semin Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Arthritis Rheum. 1992 ; 21: 275-286
17. Alijotas-Reig J, Ferrer-Oliveras R. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A preliminary first year report. Lupus. 2012 ; 21: 766-768
18. Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: The Global Anti-Phospholipid Syndrome Score. Rheumatology. 2013 ; 52: 1397-1403
19. Sciascia S, Murru V, Sanna G, Roccatello D, Khamashta MA, Bertolaccini ML. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: Evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012 ; 10: 2512-2518
20. Vikerfors A, Johansson AB, Gustafsson JT, et al. Clinical manifestations and anti-phospholipid antibodies in 712 patients with systemic lupus erythematosus: Evaluation of two diagnostic assays. Rheumatology. 2013 ; 52: 501-509
21. Swadzba J, Iwaniec T, Szczeklik A, Musiał J. Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases. J Thromb Haemost. 2007 ; 5: 1883-1889
22. Swadzba J, Iwaniec T, Pulka M, De Laat B, De Groot PG, Musial J. Lupus anticoagulant: Performance of the tests as recommended by the latest ISTH guidelines. J Thromb Haemost. 2011 ; 9: 1776-1783
23. Ruffatti A, Tonello M, Visentin MS, et al. Risk factors for pregnancy failure in patients with anti-phospholipid syndrome treated with conventional therapies: A multicentre, case-control study. Rheumatology. 2011 ; 50: 1684-1689
24. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat Rev Rheumatol. 2011 ; 7: 330-339
25. Mulla MJ, Brosens JJ, Chamley LW, et al. Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway. Am J Reprod Immunol. 2009 ; 62: 96-111
26. De Carolis S, Botta A, Santucci S, et al. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus. 2012 ; 21: 776-778
27. Reggia R, Ziglioli T, Andreoli L, et al. Primary anti-phospholipid syndrome: Any role for serum complement levels in predicting pregnancy complications?. Rheumatology. 2012 ; 51: 2186-2190
28. Alijotas-Reig J. Treatment of refractory obstetric antiphospholipid syndrome: The state of the art and new trends in the therapeutic management. Lupus. 2013 ; 22: 6-17
29. Avcin T, Cimaz R, Rozman B, et al. The Ped-APS Registry: The antiphospholipid syndrome in childhood. Lupus. 2009 ; 18: 894-899
30. Agmon-Levin N, Blank M, Zandman-Goddard G, et al. Vitamin D: An instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis. 2011 ; 70: 145-150
31. Plazak W, Gryga K, Milewski M, et al. Association of heart structure and function abnormalities with laboratory findings in patients with systemic lupus erythematosus. Lupus. 2011 ; 20: 936-944
32. Čučnik S, Kveder T, Ulcova-Gallova Z, et al. The avidity of anti-β2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: A collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus. 2011 ; 20: 1166-1171
33. Čučnik S, Kveder T, Artenjak A, et al. Avidity of anti-β2-glycoprotein I antibodies in patients with antiphospholipid syndrome. Lupus. 2012 ; 21: 764-765
34. Celińska-Löwenhoff M, Iwaniec T, Padjas A, Musial J, Undas A. Fibrin clot properties in patients with antiphospholipid syndrome. J Thromb Haemost. 2013 ; 11: 1-1322
35. Zuily S, Regnault V, Guillemin F, et al. Superficial vein thrombosis, thrombin generation and activated protein C resistance as predictors of thromboembolic events in lupus and antiphospholipid patients. A prospective cohort study. Thromb Res 2013; 132: e1-e7.
36. Lin F, Murphy R, White B, et al. Circulating levels of β2-glycoprotein I in thrombotic disorders and in inflammation. Lupus. 2006 ; 15: 87-93
37. Andreoli L, Nalli C, Motta M, et al. Anti-β2-glycoprotein I IgG antibodies from 1-year-old healthy children born to mothers with systemic autoimmune diseases preferentially target domain 4/5: Might it be the reason for their 'innocent' profile?. Ann Rheum Dis. 2011 ; 70: 380-383
38. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: Report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus. 2011 ; 20: 206-218
39. Erkan D, Harrison MJ, Levy R, et al. Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: A randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum. 2007 ; 56: 2382-2391
40. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002 ; 87: 518-522
41. Rand JH, Wu XX, Quinn AS, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: Evidence for a novel effect for an old antimalarial drug. Blood. 2010 ; 115: 2292-2299
42. Broder A, Putterman C. Hydroxychloroquine use is associated with lower odds of persistently positive antiphospholipid antibodies and/or lupus anticoagulant in systemic lupus erythematosus. J Rheumatol. 2013 ; 40: 30-33